{"name":"Allyx Therapeutics","slug":"allyx-therapeutics","ticker":"","exchange":"","domain":"","description":"Allyx Therapeutics is a biotechnology company focused on developing innovative therapies for serious diseases with significant unmet medical needs. The company's lead candidate, BMS-9894923, is currently in Phase 1 clinical trials.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxNaDRNeHhLT1hHdUt0aWhvVzFkYWtSaHlicU1udi1hUG1xd0RtaXJHaVA0UEZsdkxqVGt4YWkzUjBrT1RyVXFRTmpKMGtIaFFVQVVKcHdUYXF6RDFtUTVZMGZndVNSM2c1dFZTT2FrMktwUWQ5WEJNRGhNRDZOVnBSQ0huS1ZZcVMyRnZ0VjExSldwMlU1NEpUcQ?oc=5","date":"2025-09-25","type":"pipeline","source":"Yale Insights","summary":"Kate Heilpern: Jumping into the Deep End - Yale Insights","headline":"Kate Heilpern: Jumping into the Deep End","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxOZndhNmZRSEtwM0xPR1VhSWl1WW1BaDJ6dmpfZGlweVBUbXFkdjMwS2ZJNkp3SGpJcXdDSGVQQmh5V2JiMTBGVDA5Rkt5T2NuOWYzVFFaTk5ER3F1S3pzUk9RQ0VCOUhrT0hnQ09fZXVPNXU2WHp2U29yRXdNLU8yTS02Q1ZaWDh4bzk3QjlWdDYzbHVkaGFXUm90VlBXV3lJX0FlcmtiLW12V0p5aHpNNGtSM28?oc=5","date":"2025-04-24","type":"pipeline","source":"today.ucsd.edu","summary":"Even Light Exercise Could Help Slow Cognitive Decline in People at Risk of Alzheimer’s - today.ucsd.edu","headline":"Even Light Exercise Could Help Slow Cognitive Decline in People at Risk of Alzheimer’s","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTFBCU3I0N2g4c211dE1lRUFKUVhEWkluTFFiNU5DUDVyR2d4N0RQVFVmLVZNX19odS1XWVdxeUJ3Nkstb093cFdTeUZsT3ZqTXczYklicnhTWVRKMFNk?oc=5","date":"2025-01-28","type":"trial","source":"EurekAlert!","summary":"Study shows promise for treating core symptom of frontotemporal dementia - EurekAlert!","headline":"Study shows promise for treating core symptom of frontotemporal dementia - EurekAlert!","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwJBVV95cUxNUk0yZ0NoT2RGSnQ4ZUVEVWtNbUJhekFjRzJUSVJvb3FpXzkxZTFHN1FoWmZZd3VzWld2YTJVZzBOSk00OFRJZ0habXlxQ3FxNEdQM1ZsSS1KMWZEUUNhZmNfLW42OTdKdzdhWjVaamJ0cXpfUzdTMU5rRFJTSWpnNUJzbnIyMFpZM1pjM0Qtc19JMkdlTmZHQVFhZkNKbm1UUjhyTzB6aHNKemJnaXp4Y2p5aU5EZkktN0d3b0k2VGx6QlVqZ1NTMm93WkF0b1JaMWZySUVKTWZvSkZGZXotTUlNbHhHU0VhWjVFT0RoRHBFdl9faExHWEpHbmdmVHRfWVAzV19HMA?oc=5","date":"2024-09-26","type":"pipeline","source":"drugdiscoverytrends.com","summary":"Mixed fortunes for the neurodegeneration therapy pipeline in 2024 - drugdiscoverytrends.com","headline":"Mixed fortunes for the neurodegeneration therapy pipeline in 2024","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxPQTk1RjhIcHNLLWhTYVRZVmtIRUY0TjhlWG9lTmE1bERLbXZRTjlZa1k1c2xZY0hTUXV3bVhia19MZGRLM3NhVEFoMkkwUU8wdjNEeHVvRW9Ua25VeGRKQWlUbHJhMEFyeDhVLS1fem13QTRvTElTakFMRHlGWkR0amNsYm9QVFBHeUxR?oc=5","date":"2024-05-10","type":"trial","source":"openPR.com","summary":"Dementia Market 2032: Epidemiology Data, Pipeline - openPR.com","headline":"Dementia Market 2032: Epidemiology Data, Pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxQai1ORVJIX2duYUpua19lM3ZvMzFyUXU3Z21sUklsdHVsTEt0MVJVZGlFWS1SZFpFNFRaNW84SHIzUk5LZXhIb1M4aXBzdjVPZTJsUlZJU2ZXSHgxZzZUdU1TcjJRLU9TalhkMHBTbi13UXhpb0lFSUVyNng4cnozcDR3NkZab1BDUE9XY2RzaWp0MG1RVVlJMVVwTFRKemNfOFQ5ZUh0WTdkWFMwREQ0VUx6WmNGN1A3WTVhVw?oc=5","date":"2023-10-30","type":"trial","source":"Clinical Trials Arena","summary":"Allyx sets Phase II plans in motion after Phase Ia results for Alzheimer’s drug - Clinical Trials Arena","headline":"Allyx sets Phase II plans in motion after Phase Ia results for Alzheimer’s drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZEFVX3lxTFA2NUl4eEZOUjNiZXZ1emhHaGZJaVBnY3RkMUJxTy1sNFN6QXdsV1U3eUd4MXRmMGZ0YWlNZmlocE5QeU5mOTZqTmcwVWJWQnZLSlFaZlBoTEZ1M0FDdTdpdFlxUEs?oc=5","date":"2020-07-01","type":"pipeline","source":"Geisel School of Medicine at Dartmouth","summary":"Stephen M. Bloch, MD (D ’84) – Office of the Dean - Geisel School of Medicine at Dartmouth","headline":"Stephen M. Bloch, MD (D ’84) – Office of the Dean","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}